Menopause in the workplace has entered a different phase.
PwC frames menopause as a growth market, and the benefits market is beginning to follow that signal. Dedicated menopause benefits are being positioned as a workforce, retention, and women’s health opportunity. However, that market narrative is now colliding with a less convenient financial reality: employers are evaluating new health-benefit offerings in a cost environment that demands proof of value.
Lozen Advisory’s market correction on menopause at work named the larger problem: the market has treated awareness as adoption, access as reach, and utilization as proof of need. That assumption was already weak, the 2026 employer health-benefit cost environment makes it harder to defend.
Specifically, menopause benefits are being sold into a market where employers are already managing rising medical cost trends, pharmacy pressure, employee affordability concerns, and sharper demands for program accountability. The question is no longer whether menopause belongs in the workplace conversation. It is whether the products being sold can prove they solve the workforce risk they claim.
Rising Employer Health Benefit Costs in 2026 Are Changing the Conversation
Employers are not evaluating new benefits in a neutral budget cycle. They are evaluating them in a market where the costs of benefits per employee, is already under pressure. Mercer reported that average employer-sponsored health insurance cost reached $17,496 per employee in 2025, a 6.0% increase above inflation and wage growth. Mercer expects another 6.7% increase in 2026, pushing average cost above $18,500 per employee. Prescription drug spending rose 9.4% among large employers, and coverage of costly GLP-1 weight-loss medications expanded from 44% of large employers in 2024 to 49% in 2025.
Those figures change the benefits conversation. A menopause point solution does not arrive as a symbolic add-on in an unconstrained year. It arrives while employers are weighing pharmacy pressure, affordability concerns, plan-design tradeoffs, and the value of every specialized health program already in the portfolio.
Mercer also reported that measuring health program performance to ensure value is now an important three-to-five-year priority for more than three-quarters of large employers. That standard matters in an environment where a new point solution cannot rely on moral urgency, public narrative, or category momentum alone. It has to withstand a performance question.
Menopause Benefits Utilization: Why Low Use Is Not an Awareness Problem
The commercial case for menopause benefits is easy to understand. The affected population is large, and the workforce impact is real. Midlife women include senior executives, women in leadership, client-facing professionals, and institutional knowledge holders. Employers have legitimate reasons to care about retention, continuity risk, benefits ROI, and succession exposure.
The benefit-market case, though, has moved faster than the measurement case. PwC reported that dedicated menopause benefits rose from 4% of U.S. employers in 2023 to 25% in 2026. In the same analysis, PwC noted that utilization remains limited because many employees do not know the benefits exist or how to access them. That explanation may be partly true. Benefits can fail because employees do not know they exist, access is confusing, and the vendor is disconnected from the rest of the benefits ecosystem. But menopause benefits in the workplace introduce a separate problem. Low utilization cannot be assumed to mean low awareness, it can also reflect rational non-use.
A woman can know the benefit exists and still avoid it. She can understand the menopause transition and still decline to enter a menopause-coded pathway. She can need support and still decide that using the support would create professional information she does not want her employer, manager, benefits administrator, or vendor ecosystem to hold.
That is not an education gap. It is a collection-condition problem.
The CFO Question for Menopause Benefits: Proving Workforce Risk Reduction
The employer-facing pitch is no longer limited to care access or symptom education. Employers are being sold a workforce-risk control package. The package usually includes a retention story, a productivity story, a legal and equity risk story, manager guidance, and a policy artifact the organization can adopt or announce. The benefit is presented as a way to reduce lost productivity, support leadership continuity, standardize manager behavior, and create a defensible workplace response.
That is why the market can keep moving even when utilization is weak. The product is not being sold only as healthcare, it is being sold as measurable reassurance.
Reassurance becomes fragile, though, when the program still depends on an employee initiating access. A policy model, toolkit, leave pathway, employee template, or manager conversation guide may help the people who use it. But if the program requires someone to identify menopause-related need before the system can count her, then the employer is still measuring only the population willing to enter the pathway.
This distinction matters for CFOs because the purchased object and the measured result are not the same thing. The employer may buy a retention solution, the vendor may report participation, and the benefits team may point to program availability. But none of those measures, proves the benefit reached the population the purchase was meant to help.
Why Point Solutions Cannot Measure Menopause Workforce Risk
The CFO issue is not whether perimenopause and menopause symptoms affect work. It is whether the purchased solution reaches the workforce risk it claims to help, and whether the organization can prove it. That proof is difficult when the benefit activates only after an initiating act. If an employee must search for a menopause resource, request menopause-related leave, schedule care through a menopause-specific platform, download a template, tell HR, or use a menopause-coded accommodation pathway, then the data point is created only after she decides to enter the system. When she does not enter it, the data point is never generated.
The resulting dataset is not merely incomplete because the organization failed to analyze it well. It is incomplete because the collection condition was never met. A vendor can report engagement, registrations, completed visits, content views, referral activity, leave requests, accommodation pathways, and user satisfaction. Those metrics may be useful and show that the platform served the people who entered it. They do not show how many people did not enter. This gap exposes the inherent flaw in vendor promises: the reassurance they offer employers is fragile because vendors lack the structural power to control the professional risks driving non-use.
That distinction matters because the population most relevant to retention and succession risk may also be the population least likely to create a menopause-coded signal. Senior women have more authority to protect, more professional downside to manage, and less tolerance for being classified through a health-benefit pathway. Their non-use is not a communication failure. It is a decision.
Lozen Advisory has named that decision Tacere: the sustained, strategic practice of keeping one’s own counsel by a senior executive operating in a professional environment where disclosure carries professional risk. Tacere operates prior to any disclosure transaction, accommodation request, or formal support relationship. It does not require a stigmatized identity or a distress condition. It requires only the individual’s assessment of professional risk and the continued availability of silence as an option.
For a CFO, the implication is direct. The vendor measures users. The employer needs to understand the non-users. When the population most material to retention and succession risk is also the population most likely to practice Tacere, the gap between those two groups is where the business case weakens and where the measurement system was never designed to look.
Measuring Benefits ROI Under Health Cost Pressure
When benefit costs are rising slowly, employers may tolerate another specialized offering because it signals responsiveness and helps modernize the benefits portfolio. When average employer-sponsored health insurance costs are expected to exceed $18,500 per employee, the tolerance changes.
A menopause benefit now has to answer the same question as every other specialized health program: what measurable cost, risk, or workforce outcome does this program improve? That question cannot be answered through availability. Availability proves the employer purchased access. It does not prove the relevant population used it, trusted it, or reached support before exit risk, reduced participation, diminished ambition, or leadership continuity risk accumulated elsewhere.
This is where the CFO problem becomes unavoidable. A benefit can be well intentioned, clinically useful, and still difficult to justify as a workforce-risk intervention if its evidence base depends on voluntary use by the people least likely to use it. Although menopause support may be valuable to the people who use it, employer value cannot be inferred from the existence of the offering. Specifically, utilization data cannot be treated as a proxy for population need when the highest-cost non-use may sit outside the vendor dataset.
The financial contradiction is therefore not simply that menopause benefits cost money. The contradiction is that employers are being asked to fund a workforce solution whose performance data may exclude the very population the solution was purchased to protect.
The Menopause Benefits Measurement Gap: Employer-Sellable vs. Employer-Measurable
The perfect storm is now clear.
Health-benefit costs are rising, and employers are under pressure to measure program value. Menopause is being packaged as a workforce, retention, and benefits opportunity. Dedicated menopause benefits are increasing. Yet utilization remains limited, and the architecture of many solutions still depends on employees initiating access in a category where initiation itself may carry professional cost.
That is not a communication or branding problem. It cannot be solved by another awareness campaign. It is a measurement problem built into the benefit design.
Menopause benefits can still matter, and some women will use them, need them, and benefit from them. But employer value cannot be inferred from the existence of the offering, and utilization data cannot be treated as a proxy for population need. The market has made menopause employer-sellable. It has not yet made menopause benefits employer-measurable.
Until that changes, employers will be asked to finance access without proof of reach. In a cost-constrained health-benefit market, that is no longer a soft concern. It is the CFO problem.
That is why the investment question cannot be answered by asking whether menopause benefits are well intended, clinically useful, or culturally current. The better question is whether the organization can prove that the benefit reaches the workforce risk it was purchased to help.
Are menopause benefits worth investing in for our workforce?
Menopause benefits may be worth investing in when the organization can prove more than access. The question is not whether menopause affects work. The question is whether the benefit reaches the workforce risk it was purchased to address.
A menopause benefit that depends entirely on voluntary utilization may serve the employees who enter the system, but it cannot prove that it reached the women most likely to avoid a menopause-coded pathway. For CFOs, that distinction matters. Availability is not the same as adoption. Utilization is not the same as need. A low-use benefit can still point to a real workforce problem, but it cannot be treated as evidence that the problem has been measured.
The investment case is strongest when menopause benefits are evaluated alongside retention risk, leadership continuity, disclosure-dependent data, and the cost of non-use. Lozen Advisory’s market correction press release on the menopause benefits market explains why the market must move beyond awareness and adoption claims.
Request a Strategic Briefing
Lozen Advisory works with organizations examining benefits ROI, leadership retention, workforce-risk visibility, and the measurement gaps created when utilization depends on disclosure.
